PARENTERAL 1,25-DIHYDROXYCHOLECALCIFEROL IN HEPATIC OSTEOMALACIA

被引:48
作者
LONG, RG
VARGHESE, Z
MEINHARD, EA
SKINNER, RK
WILLS, MR
SHERLOCK, S
机构
[1] ROYAL FREE HOSP,DEPT MED,LONDON NW3 2QG,ENGLAND
[2] ROYAL FREE HOSP,RENAL UNIT,LONDON NW3 2QG,ENGLAND
[3] ROYAL FREE HOSP,METAB UNIT,LONDON NW3 2QG,ENGLAND
[4] ROYAL FREE HOSP,DEPT CHEM PATHOL,LONDON NW3 2QG,ENGLAND
基金
英国医学研究理事会;
关键词
D O I
10.1136/bmj.1.6105.75
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite regular long-term parenteral vitamin D2treatment, four patients with biliary cirrhosis had multiple symptoms of bone disease and bone biopsy specimens showed osteomalacia without osteoporosis. Three patients also had a proximal myopathy. Plasma calcium values (after correction for albumin), phosphorus, magnesium, and serum 25-hydroxy-vitamin D were within normal limits. Treatment with 1,25-dihydroxycholecalciferol (l,25-(OH)2D3) relieved symptoms in three of the four patients and improved those in the fourth. Histological examination of bone showed improvement in all four patients, but serum and urinary biochemical changes were not pronounced. We conclude that l,25-(OH)2D3treatment has a beneficial effect on bone and muscle in hepatic osteomalacia, either because vitamin D 1-hydroxylation fails in biliary cirrhosis or because hepatic osteomalacia is resistant to vitamin D2metabolites. © 1978, British Medical Journal Publishing Group. All rights reserved.
引用
收藏
页码:75 / 77
页数:3
相关论文
共 21 条